Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07234981 | PSMA-PET Guided De-escalation of Salvage Radiation Treatment in Recurrent Prostate Cancer | recruiting | Phase 2 | 54 | University of NebraskaOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07495124 | IGFBP-2 Vaccine to Prevent Ovarian Cancer Progression in Patients With Serologic Detection of Recurrence | recruiting | Phase 2 | 26 | University of WashingtonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07638410 |
| Prehabilitation in High-risk Oncologic Surgery |
| recruiting |
| N/A |
| 180 |
| Fox Chase Cancer CenterOTHER |
| 1 |
| Sep 21, 2026 |
| clinicaltrials |
| NCT07831824 | Dose Optimization and Diagnostic Performance in Prostate Cancer (SPARROW [Staging Prostate Cancer With Advanced RM2 Radiotracer Oncologic Workup])(SPARROW) | recruiting | Phase 2 / Phase 3 | 408 | Lantheus Medical ImagingINDUSTRY | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831902 | Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial Cancer(NSMP-ORANGE) | recruiting | Phase 3 | 600 | University College, LondonOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03943316 | Prospective Laboratory Study Biologic Specimens and Tumor Tissue of Patients With Cancer | recruiting | — | 500 | New Mexico Cancer Research AllianceOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04038619 | Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients | recruiting | Phase 1 | 40 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT04752826 | BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | recruiting | Phase 1 / Phase 2 | 250 | BioInvent International ABINDUSTRY | 7 | Sep 18, 2026 | clinicaltrials |
| NCT06085729 | Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) | recruiting | Phase 1 / Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06678126 | Adaptive Versus Non-adaptive Radiotherapy and 2 Bladder Filling Instructions for Patients With Intermediate or High Risk Localized Prostate Cancer (ARP) | recruiting | Phase 2 | 104 | Scott TyldesleyOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT06952803 | A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation(EvoPAR-PR02) | recruiting | Phase 3 | 700 | AstraZenecaINDUSTRY | 28 | Sep 18, 2026 | clinicaltrials |
| NCT07365995 | A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 3 | 736 | BioNTech SEINDUSTRY | 4 | Sep 18, 2026 | clinicaltrials |
| NCT07497919 | A Study of Becotatug Vedotin Combined With Pucotenlimab in the Treatment of EGFR-Positive Advanced Penile Cancer | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07548164 | Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer | recruiting | Phase 3 | 224 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07650240 | Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial(SPARKLE) | recruiting | Phase 2 | 202 | Mayo ClinicOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05011383 | High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers(VA-BAT) | recruiting | Phase 2 | 51 | VA Office of Research and DevelopmentFED | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05155046 | 18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy | recruiting | Phase 2 | 130 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05316129 | Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer | recruiting | Phase 1 | 10 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05475171 | Triage of Advanced Cervical Cancer Through Immunotherapy Induction (TRACTION) | recruiting | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05616650 | Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor | recruiting | Phase 2 | 42 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05665738 | Two-fraction HDR Monotherapy for Localized Prostate Cancer | recruiting | N/A | 17 | University of California, San FranciscoOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT05758688 | PROton Therapy for Post Surgical Treatment of GYNecologic Cancer(PROPS GYN) | recruiting | Phase 2 | 25 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06340568 | A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer(Fern-EC-01) | recruiting | Phase 3 | 480 | BioNTech SEINDUSTRY | 26 | Sep 17, 2026 | clinicaltrials |
| NCT06568094 | A Study of HRS-5041 Tablets Combined With Antitumor Therapy in Subjects With Advanced Prostate Cancer | recruiting | Phase 1 / Phase 2 | 100 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06582446 | Artificial Intelligence to Personalize Prostate Cancer Treatment (the HypoElect Trial)(HypoElect) | recruiting | Phase 2 | 30 | German Oncology Center, CyprusOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT06925737 | A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) | recruiting | Phase 3 | 1,440 | Merck Sharp & Dohme LLCINDUSTRY | 35 | Sep 17, 2026 | clinicaltrials |
| NCT06952504 | A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)(TroFuse-033) | recruiting | Phase 3 | 1,123 | Merck Sharp & Dohme LLCINDUSTRY | 34 | Sep 17, 2026 | clinicaltrials |
| NCT07020117 | A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors | recruiting | Phase 1 | 150 | Aktis Oncology, Inc.INDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07318558 | A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)(TroFuse-021) | recruiting | Phase 3 | 900 | Merck Sharp & Dohme LLCINDUSTRY | 29 | Sep 17, 2026 | clinicaltrials |
| NCT07691697 | PSMA PET-Staged Comprehensive Progression-Directed Radiotherapy for Limited Progression in Prostate Cancer(PSMA-OLIGO-PRO) | recruiting | — | 1,000 | Affidea Nu-med Center of Oncological DIagnostics and TherapyOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07813637 | Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC(PSMA-013-001) | recruiting | Phase 1 | 110 | Janux TherapeuticsINDUSTRY | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07818850 | Vagina-View Safety and Imaging Feasibility(Vagina-View) | recruiting | N/A | 10 | University Health Network, TorontoOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07826858 | SPECTRA: Intraoperative Hyperspectral Imaging for Prostate Cancer(SPECTRA) | recruiting | N/A | 26 | Massimo ValerioOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT01834001 | Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy | recruiting | — | 300 | National Cancer Institute (NCI)NIH | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04273061 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity(CAPTIV-8) | recruiting | Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06366347 | ALPINE: Maintenance Letrozole/Abemaciclib | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06409052 | Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women | recruiting | — | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06873555 | A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Heronova PharmaceuticalsINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07116213 | Clinical Research on Moderately Hypofractionated Adaptive Postoperative Radiotherapy for High-Risk Endometrial Cancer | recruiting | N/A | 20 | Xiaorong HouOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07489287 | GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer | recruiting | Phase 1 | 18 | Roswell Park Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07549256 | Cannabidiol for Pain Relief of Patients With End-stage mCRPC(ProCan) | recruiting | Phase 2 | 58 | Regionshospital NordjyllandOTHER_GOV | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07584161 | MH-ART vs CF-IMRT in Postoperative Cervical/Endometrial Cancer(ARTISAN) | recruiting | N/A | 228 | Xiaorong HouOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07718854 | Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer | recruiting | Phase 2 | 50 | Tufts Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07821879 | Routine Shallow-coverage Whole Genome Sequencing Testing of Liquid-based Cervical Smears for the Early Diagnosis of Ovarian Cancer(SHALLOW ROUTE) | recruiting | — | 50 | Institut Claudius RegaudOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07822646 | A Phase 3 Study of Manganese-primed Immunochemotherapy in Patients With Advanced Ovarian Cancer | recruiting | Phase 3 | 120 | Chinese PLA General HospitalOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04073706 | Sentinel Node Biopsy in Endometrial Cancer(ENDO-3) | recruiting | Phase 3 | 760 | Queensland Centre for Gynaecological CancerOTHER_GOV | 7 | Sep 15, 2026 | clinicaltrials |
| NCT04104529 | Clinico-biological Database in Patients Treated With Metabolic Radiotherapy in the Nuclear Medicine Department(BCB RIV) | recruiting | N/A | 350 | Institut du Cancer de Montpellier - Val d'AurelleOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
Data updated 5 days agoSource updated Sep 21, 2026source: clinicaltrials